No Data
No Data
The TOPIX Gross Index rose significantly, with growth core 20 stocks all expanding gains.
Tokyo Stock Exchange Growth Market Index is at 868.64, up 24.20 points, with a volume of 0.2 billion 33.78 million shares and a trading value of 185.1 billion yen. The TSE Growth Market 250 Index is at 677.13, up 21.27 points, with a volume of 0.1 billion 77.28 million shares and a trading value of 159.2 billion yen. Today's growth market has seen both the TSE Growth Market Index and TSE Growth Market 250 Index continue to rise significantly. The number of rising stocks is 291, the number of falling stocks is 245, and unchanged is 45. The US stock market on the 11th was mixed. The Dow average was up 32.39 dollars.
Stocks hitting the upper or lower price limit in the afternoon session.
■Stocks that hit the upper limit<194A>WOLVES HAND <4196>NEO MARKETING <4288>AZJENT <4443>Sansan <4582>Shin-Biyo Seiyaku <5250>Main Board Strategy <6532>Baycurrent Consulting■Stocks that hit the lower limit<4586>Medirex※includes temporary upper and lower limits (indicative value)
Emerging Market Stocks Digest: Creamer plummets, Boardlua surges.
<4586> Medorec 97 -50 stop loss. It has been disliked by the market due to downward revision of performance estimates. For the FY 2024 performance estimate, revenue has been revised downward from ¥0.42 billion to ¥0.44 billion (a decrease of 44.8%), and operating loss has been revised downward from a deficit of ¥1.183 billion to a deficit of ¥1.298 billion, assuming approval and milestone revenue, product revenue and cost of goods manufactured for MRX-5LBT are recognized in FY 2024.
Medrexx - Stop selling at low prices, downward revision of financial estimates for this fiscal year.
There is a stop in the downward trend of the sale price. The financial estimates have been revised downwards and are being disliked. For the performance outlook for the year ending December 2024, the revenue has been revised downward from 0.4 billion 42 million yen to 0.2 billion 44 million yen (a decrease of 44.8% in sales growth), and the operating loss has been revised downward from a deficit of 1.1 billion 83 million yen to a deficit of 1.2 billion 98 million yen. The completion report notification from the MRX-5LBT review reception has removed the prospect of recognizing milestone revenue, product sales revenue, and cost of goods manufactured in December 2024.
Medrx: Announcement of revised financial estimates.
Medrx Sees Wider FY Net Loss at Y1.26B
GROUP New Forecast Prior For Year To Dec 2024 Forecast Revenue Y244.00 mln Y442.00 mln Operating Profit (Y1.30 bln)
No Data